British American Tobacco (BAT) is facing a significant shareholder lawsuit filed at London’s High Court on February 27, 2026. More than 100 current and former UK shareholders accuse the company of failing to disclose critical information about its North Korea operations to the stock market from 2007 to 2023. The claim, represented by law firm Fox Williams, centers on BAT’s alleged nondisclosure of U.S. sanctions breaches, following a $635 million settlement with U.S. authorities in 2023. BAT has not yet responded publicly to the allegations.
Background on Sanctions Violations
The roots trace back to 2023, when BAT’s Singapore subsidiary, BAT Marketing Singapore (BATMS), admitted to conspiring to violate U.S. sanctions by selling tobacco products to North Korea and committing bank fraud from 2007 to 2017. U.S. prosecutors revealed BAT used a third-party Singapore company under its control to sell over $400 million in tobacco, evading sanctions imposed due to North Korea’s nuclear program. The U.S. Justice Department and Treasury’s OFAC imposed penalties totaling $629-635 million, marking one of the largest sanctions-related settlements. BAT entered a deferred prosecution agreement, stating it had improved practices post-2017.
Shareholder Allegations in Detail
Claimants argue BAT misled investors by not fully revealing ongoing North Korea risks beyond the 2017 cutoff, extending to 2023. Fox Williams stated: “The claim alleges that BAT failed to properly publish information to the stock market about its business operations in North Korea since 2007 to 2023.” This nondisclosure allegedly caused share price drops after the U.S. settlement news, harming investors. A parallel lawsuit by another group, represented by Stewarts, was filed the same day, though details remain undisclosed.
BAT’s Prior Admissions and Response
BAT publicly claimed in 2007 it had ceased North Korea operations, yet continued via proxies, per U.S. charges. The 2023 settlement involved guilty pleas from BATMS and highlighted “an elaborate scheme to circumvent U.S. sanctions,” as noted by Assistant Attorney General Matthew G. Olsen. BAT emphasized the issues were historical and limited to its subsidiary, with no admission of direct parent liability. No immediate comment on the 2026 lawsuit has been issued.
Legal and Market Implications
The lawsuits invoke UK group action rules, allowing aggregated claims for efficiency. The undisclosed value could run into millions, depending on proven losses tied to BAT’s FTSE 100 share price movements post-2023 disclosure. Analysts note rising scrutiny on corporate sanctions compliance amid global tensions. For BAT, already navigating tobacco regulations and nicotine transitions, this adds compliance risks. London’s High Court will determine if claims proceed to trial.
Broader Context: Sanctions and Tobacco Industry
U.S. sanctions under the International Emergency Economic Powers Act (IEEPA) target North Korea’s weapons funding, including illicit trade. Tobacco giants like BAT faced probes as Pyongyang evaded bans via intermediaries in Asia. Similar cases include other firms penalized for indirect dealings. This lawsuit underscores shareholder activism on ESG and compliance failures. BAT’s Korea exposure highlights challenges for multinationals balancing markets and geopolitics.
Timeline of Key Events
Expert Reactions and Future Outlook
Legal experts view the case as testing disclosure duties under UK Financial Conduct Authority rules. Shareholders must prove BAT’s omissions were material and caused quantifiable harm. BAT shares dipped slightly on lawsuit news, amid broader market volatility. The company, a global leader in cigarettes and vapes, faces ongoing U.S. scrutiny but reports strengthened controls. Resolution could take years, potentially influencing peer compliance.